In the absence of a submission from the holder of the marketing authorisation, telmisartan (Micardis®) cannot be endorsed for use within NHS Wales for cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with manifest atherothrombotic cardiovascular disease or diabetes with at least one cardiovascular risk factor.